What is apotex's current status in ruxolitinib generic development?

I don’t have real-time visibility into Apotex’s current development status for a ruxolitinib generic. Status depends on the market (US, Canada, EU, etc.) and on patent/ANDA litigation progress, which can change month to month.

If you’d like, I can look up the latest public information. To narrow it down, please tell me:
- Which market are you interested in (US, Canada, EU, or another country)?
- Do you want regulatory status (ANDA filings and approvals), patent litigation status, or actual commercial launch status?

If you want to check yourself right now, you can look at:
- US: FDA Orange Book entry for ruxolitinib to see any APOTEX ANDA filings, patent status, and approvals; plus any court docket entries for Incyte v. Apotex (PACER or law firm releases) to see litigation progress.
- Canada/other: Health Canada/EMA records and any company press releases for announcements on generic development.
- General: recent press releases from Apotex or Incyte and major pharma news outlets.

If you’d like, say “Yes, please search the web,” and specify the market, and I’ll pull the latest public info and summarize Apotex’s current status.